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T Interval Variability and
pontaneous Ventricular Tachycardia or
ibrillation in the Multicenter Automatic
efibrillator Implantation Trial (MADIT) II Patients
ark C. Haigney, MD,* Wojciech Zareba, MD, PHD,† Philip J. Gentlesk, MD,*
obert E. Goldstein, MD,* Michael Illovsky, MD,* Scott McNitt, PHD,† Mark L. Andrews, PHD,†
rthur J. Moss, MD,† and the MADIT II Investigators
ethesda, Maryland; and Rochester, New York
OBJECTIVES This study aimed to determine whether increased QT interval variability is associated with an
increased risk for ventricular tachycardia (VT) or ventricular fibrillation (VF), documented by
interrogation of the implantable cardioverter-defibrillator (ICD), in patients enrolled in the
Multicenter Automatic Defibrillator Implantation Trial (MADIT) II.
BACKGROUND Unstable repolarization has been proposed as a risk factor for re-entrant arrhythmias, but
confirmatory data from clinical trials are lacking.
METHODS The QT variability was assessed in 10-min, resting high-resolution electrocardiogram
recordings at study entry using a semiautomated algorithm that measured beat-to-beat QT
duration in 817 MADIT II patients. The incidence of VT/VF requiring device therapy was
determined by ICD interrogation.
RESULTS Median normalized QT variability (QTVN) was 0.179 and 0.125, respectively, in patients
with VT/VF versus those without VT/VF (p 0.001); QTVI (QTVN adjusted for heart rate
variance) also was significantly (p  0.05) higher in VT/VF patients than in those without
VT/VF. Either QTVN or QTVI was linked with a significantly higher probability of VT/VF:
two-year risk of VT/VF from Kaplan-Meier curves was 40% in highest quartile versus 21%
in lower quartiles for QTVN, and 37% versus 22% for QTVI (p  0.05 for each). In
multivariate Cox regression models adjusting for clinical covariates (race, New York Heart
Association functional class, time after myocardial infarction), top-quartile QTVI and
QTVN were independently associated with VT/VF (hazard ratio for QTVN 2.18, 95%
confidence interval [CI] 1.34 to 3.55, p  0.002; hazard ratio for QTVI 1.80, 95% CI 1.09
to 2.95, p  0.021).
CONCLUSIONS In postinfarction patients with severe left ventricular dysfunction, increased QT variability, a
marker of repolarization lability, is associated with an increased risk for VT/VF. (J Am Coll
Cardiol 2004;44:1481–7) © 2004 by the American College of Cardiology Foundationh
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she Multicenter Automatic Defibrillator Implantation Trial
MADIT) II demonstrated that prophylactic defibrillator im-
lantation in patients with a prior myocardial infarction and an
jection fraction of 0.30 reduced the risk of death from
9.8% to 14.2% at 20 months (1). Conventional risk stratifi-
ation failed to predict which patients would experience ven-
ricular tachycardia (VT) or ventricular fibrillation (VF) neces-
itating either an implantable cardioverter-defibrillator (ICD)
hock or antitachycardia pacing. In the Multicenter Unsus-
ained Tachycardia Trial (MUSTT) registry, subjects with a
egative electrophysiologic study experienced an unacceptably
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2). Moreover, inducibility at electrophysiologic study did not
redict subsequent mortality, arrhythmia recurrence, or ar-
hythmic death in the Antiarrhythmics Versus Implantable
efibrillators (AVID) trial (3). The failure of conventional
pproaches to arrhythmia prediction may reflect a limited
nderstanding of the mechanism of VT/VF in post-infarction
atients with significant left ventricular dysfunction.
Unstable ventricular repolarization may contribute to the
evelopment of VT/VF (4,5). The induction of T-wave
lternans by atrial pacing or exercise has been found to
redict subsequent spontaneous or inducible ventricular
rrhythmias in several small (6–8) and two large studies
9,10). While T-wave alternans is rarely found in the
bsence of pacing or exercise-induced tachycardia, resting
atients with dilated cardiomyopathy (11) or congenital
ong QT syndromes manifest increased beat-to-beat vari-
bility in the QT interval duration (12). Atiga et al. (13)
tudied 95 patients undergoing electrophysiologic study and
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Repolarization and VT/VF October 6, 2004:1481–7ompared both invasive and noninvasive indexes of arrhyth-
ic risk, including T-wave alternans ratio during atrial
acing. In a stepwise multiple logistic regression, the pres-
nce of increased QT variability was the only variable
ssociated with sudden death.
To further investigate the relation between repolarization
ability and spontaneous VT/VF, we measured QT variabil-
ty at rest in the MADIT II population. In this prospec-
ively designed MADIT II substudy, we hypothesized that
ncreased QT variability would be independently associated
ith subsequent VT/VF requiring therapy from the ICD.
ETHODS
atient population and data acquisition. The study pop-
lation was derived from the 1,232 patients in the MADIT
I study population. Each patient had a history of myocar-
ial infarction and an ejection fraction of 0.30 or less (1). As
art of MADIT II enrollment, patients underwent resting
olter monitoring for 10 min, using a high-resolution
igital recording system (3 orthogonal leads, 1,000-Hz
Table 1. Clinical Characteristics of MADIT II
Percentile (the Highest Quartile Versus Three
Clinical variables
Mean age (yrs)
Females
Diabetes
CHF NYHA functional class II–IV
Median time from MI until enrollment (months)
Hypertension requiring treatment
Ejection fraction
Coronary bypass surgery
Blood urea nitrogen (mg/dl)
Inducible at electrophysiologic study
Mean heart rate (beats/min)
Left bundle branch block
Medications
Beta-blockers (baseline)
Digitalis (baseline)
Ace inhibitor (baseline)
Diuretic (baseline)
Lipid-lowering (baseline)
Only p values 0.05 are shown, all other p values were non
CHF  congestive heart failure; MADIT  Multicent
Abbreviations and Acronyms
CI  confidence interval
HRv  heart rate variance
ICD  implantable cardioverter-defibrillator
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
QTVI  QT variability index
QTVN  QT variability (numerator)
VF  ventricular fibrillation
VT  ventricular tachycardiainfarction; NYHA  New York Heart Association; QTVI  QTampling frequency, 12-bit resolution, SpaceLab-Burdick
632 recorder, Spacelab-Burdick, Milton, Wisconsin). The
ecording electrodes were standard silver-silver chloride
onductors (Blue Sensor, Linthicum, Maryland) arrayed in
n XYZ configuration (i.e., lead X corresponding to limb
ead I, lead Y to aVF, and lead Z roughly to V3, with the
ositive electrode anterior and negative pole posterior at the
ip of the right scapula). This short recording period,
onsidered adequate for measurements of heart rate vari-
bility (14) was chosen due to the practical limitations of
cquiring more prolonged high-quality electrocardiogram
ECG) in such a large population. Patients were excluded if
heir ECG demonstrated rhythm other than sinus; bundle
ranch block was not an exclusion criterion. All subjects
ave informed, written consent at entry, and the institu-
ional review board at each hospital approved the study.
T variability algorithm. We applied the QT variability
lgorithm described by Berger et al. (11), provided courtesy
f Ronald Berger and Barry Fetics, Johns Hopkins Univer-
ity. Briefly, the analysis was performed offline, the operator
electing the ECG lead with the least noise and the most
onsistent T-wave morphology. The operator chose the X
ead in 30% of subjects, the Y lead in 26%, and the Z lead
n 44%. For each patient, the operator defined a template
RST configuration and a reference QT interval by select-
ng the beginning of the QRS complex and the end of the
epolarization complex for one representative beat. A pro-
rammable blanking period removed the QRS complex.
he algorithm then applied the template to each subsequent
eat, and a QT interval was derived for that beat based on
“best-fit” for the entire T-wave. All deflections that might
ients With QTVI Dichotomized at 75th
er Quartiles)
QTVI <75th
Percentile
(n  613)
QTVI >75th
Percentile
(n  204)
p
Value
63 62
16% 24% 0.008
31% 48%  0.001
59% 71% 0.002
54 47
51% 60% 0.030
23.3% 22.7% 0.182
56% 58%
21 25 0.012
39% 30%
70 78  0.001
16% 18%
65% 66%
52% 67%  0.001
78% 77%
71% 79% 0.019
69% 68%
cant.
omatic Defibrillator Implantation Trial; MI  myocardialPat
Low
signifi
er Autvariability index.
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October 6, 2004:1481–7 Repolarization and VT/VFelate to repolarization were included in the template; the
nd of repolarization was determined by the final return to
he isoelectric baseline. The U waves did not have a
isproportionate effect on the QT interval determination
ecause they were of low amplitude and had less influence
han the T-wave on the sum of squared differences. Because
f the blanking period, the algorithm excluded variability in
RS morphology as a source of measured QT variability.
Because QT variability in normal subjects is driven to a
arge degree by heart rate variability, in one analysis we used
metric incorporating assessment of heart rate variability
11). A heart rate time series was constructed from the
equence of RR intervals. The heart rate mean (HRm) and
eart rate variance (HRv) and QT interval mean (QTm)
nd QT interval variance (QTv) were computed from the
espective time series. A normalized QT variability index
QTVI) was then derived according to the equation: QTVI
log10 [(QTv/QTm
2)/(HRv/HRm2)].
The QTVI, therefore, is the log ratio between the QT
nterval and heart rate variability, each normalized by the
quared mean of the respective time series. In order to index
he extent of repolarization lability without adjustment for
eart rate variability, we also calculated the QT variance
ormalized for the mean QT (QTVN) as: QTVN 
Tv/QTm2. The digitized ECG recordings were analyzed
y a single physician (P.J.G.), who was blinded to the
reatment allocation and outcomes of the subject. Because
he measure is semiautomated, selection of the QT interval
s the only significant source of interobserver variability. We
ad two independent operators analyze 50 records randomly
elected from the MADIT II database. The correlation
etween the results was extremely good for both QTVI (r
.983) and QTVN (r  0.976).
able 2. Clinical Variables Significantly Associated With High-
isk Quartile of QTVI in the Multivariate Logistic Regression
odel
Hazard
Ratio* 95% CI p Value
YHA functional class II 1.51 1.05–2.15 0.025
iabetes 1.70 1.21–2.39 0.002
UN 25 1.62 1.13–2.31 0.009
igitalis 1.67 1.18–2.35 0.004
Odds of appearing in the high-risk (highest) quartile of QTVI if the characteristic is
resent.
BUN  blood urea nitrogen; CI  confidence interval; NYHA  New York
eart Association; QTVI  QT variability index.
able 3. Comparison of Studied Electrocardiogram Parameters in
No VT/VF
(n  359)
Mean  SD Median (25th; 75th percentile)
R 70 14 69 (59; 80)
DNN 42 35 31 (20; 49)
TVI 0.94  0.60 0.97 (1.37; 0.55)
TVN 0.25  0.56 0.13 (0.06; 0.23)
R  heart rate; ICD  implantable cardioverter defibrillator; QTVI  QT variabi
F  ventricular fibrillation; VT  ventricular tachycardia.etermination of clinical end points. The occurrence of
T or VF requiring defibrillator therapy (either antitachy-
ardia pacing or defibrillator shock) was determined by
eriodic interrogation of the implanted device as deter-
ined by the trial protocol. The results of these device
nterrogations were reviewed by the MADIT II Data
oordinating Center, which determined the appropriate-
ess of therapy. The appropriate therapy for VT/VF was the
nd point in patients randomized to ICD therapy, and
ll-cause mortality was the end point in patients randomized
o conventional therapy.
tatistical analysis. We prespecified a high-risk subgroup
f studied patients by identifying individuals in the highest
uartile (75th percentile) of distribution of QTVI and
TVN values. Dichotomized variables were compared by
hi-square test, while t test was used for continuous vari-
bles that were normally distributed; the Wilcoxon rank-
um test was used for nonnormally distributed variables.
aplan-Meier curves with log-transformed data were used
o address our primary hypothesis testing the association
etween increased QT variability and probability of first
ppropriate defibrillator therapy for VT or VF in patients
andomized to ICD therapy. The association between QT
ariability and end points was next tested with the Cox
roportional-hazards regression model after stratification
ased on enrolling center, using a center-pooling algorithm.
imilar analyses were performed for testing the association
etween QT variability and all-cause mortality in patients
andomized to the conventional arm and in those random-
zed to ICD therapy.
ESULTS
f 1,232 subjects in the trial, 310 Holter records were
nitially excluded by the core laboratory at University of
ochester; 111 were paced, 98 were in atrial fibrillation, 76
ere uninterpretable due to noise, and the remainder (n 
5) had no recording performed. Of the remaining records
n  912), 95 were excluded due to atrial fibrillation/flutter
n  64), ventricularly paced rhythm (n  2), excess noise
n  8), high-degree heart block (n  2), or ectopy, which
he data-processing algorithm could not distinguish from
inus rhythm (n  19). Of 817 subjects who were success-
ully analyzed, 476 (58%) were randomized to defibrillator
mplantation, and 341 (42%) to conventional therapy with-
jects With and Without Appropriate ICD Therapy for VT/VF
VT/VF
(n  104)
Mean Median (25th; 75th Percentile) p Value
71 13 71 (64; 80) 0.276
41 31 35 (19; 50) 0.620
0.80  0.56 0.85 (1.24; 0.36) 0.037
0.39 0.59 0.18 (0.08; 0.38) 0.001
ex; QTVN  QT variability; SDNN  standard deviation of normal RR intervals;Sub
lity ind
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Repolarization and VT/VF October 6, 2004:1481–7ut defibrillator. The univariate comparisons of important
linical variables between the highest quartile for QTVI and
he remaining three quartiles in these 817 subjects are
ummarized in Table 1. In a multivariate logistic regression
Table 2), patients with increased QT variability (the
ighest quartile) manifested evidence of more severe disease
ith more frequent New York Heart Association functional
lass II, higher blood urea nitrogen levels, more frequent
iabetes, and more frequent digoxin use.
T variability and ICD therapy. Of 742 subjects ran-
omized to defibrillator implantation in the trial, 476 had
igital ECG recordings that were successfully analyzed.
efibrillator interrogations were not available for 13 sub-
ects. The mean QTVI was significantly higher in the 104
ubjects subsequently requiring an appropriate therapy for
T/VF during a mean 21  12 month follow-up, consis-
ent with a higher degree of instability in repolarization
Table 3). Interestingly, the normalized HRv was not
ifferent between those who experienced VT/VF and those
59 who did not, suggesting that the difference in the QTVI
as driven by an increase in the unadjusted QT variability,
TVN. Indeed, mean and median QTVN were signifi-
antly higher in the VT/VF group compared with those
ho did not experience VT/VF.
Of the subjects in the highest quartile for QTVI
0.52 log units), 37% experienced an episode of VT/VF
y two years, compared with 22% in the lower three
uartiles. The time until first appropriate therapy for
T/VF was significantly shorter in the top quartile for
TVI (p  0.01) (Fig. 1, top panel). Even greater separa-
ion in the Kaplan-Meier curves is found when comparing
he time until first therapy between the highest quartile for
TVN versus the lower quartiles (0.257 U, p  0.001)
Fig. 1, bottom panel). Although most of the arrhythmic
vents in these subjects represented VT, those in the top
uartile for QTVN were also more likely to experience
F compared with those in the lower quartiles (p  0.046
y Kaplan-Meier analysis). In the multivariate Cox
roportional-hazards regression model, a QTVI 0.52
og units was an independent risk factor for VT/VF, with a
azard ratio of 1.80 (95% confidence interval [CI] 1.09 to
.95, p  0.021) after adjusting for relevant and significant
linical covariates (race, New York Heart Association func-
ional class, time after myocardial infarction); QTVN was a
omewhat stronger predictor using the same model, with a
azard ratio for VT/VF of 2.18 (95% CI 1.34 to 3.55, p 
.002). Table 4 shows results of additional Cox analysis
fter adjustment for clinical factors differentiating patients
ith higher and lower levels of QTVN. Again, QTVN was
ignificantly associated with VT/VF during a long-term
ollow-up. Finally, neither ejection fraction (dichotomized
t  or 25%; hazard ratio 1.12, 95% CI 0.79 to 1.57, p 
.53) nor inducibility of VT/VF during programmed ven-
ricular stimulation (hazard ratio 1.26, 95% CI 0.86 to 1.86,
 0.24) was a significant predictor of spontaneous VT/VFesulting in ICD therapy.Because the identification of the high-risk subset was
respecified before the data analysis, we also tested whether
istribution of QTVN by quartile might influence the
esults. As shown in Figure 2, patients with QTVN in the
ower three quartiles were at very similar risk of VT/VF,
ignificantly lower than patients with QTVN in the high-
isk quartile.
igure 1. Cumulative probability of first appropriate defibrillator therapy
or ventricular tachycardia (VT) or ventricular fibrillation (VF) in patients
ith QT variability (QTVN) in the highest quartile versus lower three
uartiles for QT variability index (QTVI) (top panel) and QTVN (bottom
anel). P value from log-rank statistics. ICD  implantable cardioverter
efibrillator.
able 4. High-Risk Quartile of QTVN in the Multivariate Cox
odel Predicting Appropriate Therapy for VT/VF After
djustment for Relevant Clinical Covariates*
Hazard
Ratio 95% CI p Value
YHA functional class II 1.28 0.77–2.16 0.339
iabetes 0.61 0.37–0.99 0.049
UN 25 1.48 0.88–2.51 0.140
igitalis 1.07 0.66–1.75 0.785
TVN (HRQ) 2.20 1.36–3.56 0.001
Clinical covariates that were significantly different in patients with QT variability
QTVN) in the high-risk quartile (HRQ) than those having lower QTVN values
ere forced in the model.Abbreviations as in Tables 2 and 3.
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October 6, 2004:1481–7 Repolarization and VT/VFSubjects with bundle branch block were not excluded
rom this analysis. Because such individuals may be at
igher risk for arrhythmia, we reanalyzed the time until first
pisode of VT/VF after removing all individuals with QRS
120 ms. The remaining subjects in the top quartile for
TVN experienced VT/VF significantly sooner than those
n the lower quartiles (p  0.001) (Fig. 3).
urvival in the conventional and defibrillator arms. Ad-
quate digital ECG recordings were available in 341 sub-
ects randomized to conventional therapy. There was no
ifference in the survival of subjects in the highest quartile
nd the lower quartiles for either QTVI or QTVN. There
as a trend towards an increase in presumed arrhythmic
ortality in the highest quartile for QTVN (13% vs. 8.5%,
 0.23); the total number of events, however, was low (n
32).
igure 2. Cumulative probability of first appropriate defibrillator therapy
or ventricular tachycardia or fibrillation in patients with QT variability
QTVN) by quartile of QTVN. P value from log-rank statistics. ICD 
mplantable cardioverter defibrillator; VF  ventricular fibrillation; VT 
entricular tachycardia.
igure 3. Cumulative probability of first appropriate defibrillator therapy
or ventricular tachycardia (VT) or ventricular fibrillation (VF) in patients
ithout bundle branch block with QT variability (QTVN) in the highest
uartile versus lower three quartiles. P value from log-rank statistics. ICDeimplantable cardioverter defibrillator.Within the defibrillator arm of the study, the survival in
he highest quartile for QTVN did not differ from the lower
uartiles (Fig. 4, top panel). However, the subjects in the
ighest quartile for QTVI demonstrated a significantly
igher incidence of death compared with the other quartiles
Fig. 4, bottom panel). The increased deaths in this group
ere predominately due to cardiac causes that were not
ssociated with sudden demise (19 of 109 vs. 9 of 330 for
he combined lower quartiles, p  0.02 by chi-square). The
op quartile for QTVN was not associated with an increase
n nonsudden cardiac deaths (5 of 105 vs. 13 of 334, p 
.70). These findings suggest that HRv, the denominator in
he QTVI formula, is responsible for the association be-
ween QTVI and mortality in ICD patients; QTVN, which
s not adjusted for HRv, appears to be more specific for
rrhythmic events.
ISCUSSION
he principle findings of this study are: 1) that varying
egrees of repolarization lability are present at rest in
atients with previous myocardial infarction and reduced
igure 4. Cumulative probability of survival in patients randomized to
efibrillator implantation with QT variability (QTVN) in the highest
uartile versus lower three quartiles for QT variability index (QTVI) (top
anel) and QTVN (bottom panel). P value from log-rank statistics.jection fraction; 2) those subjects in the highest quartile for
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Repolarization and VT/VF October 6, 2004:1481–7epolarization instability also had evidence of significantly
ore advanced disease, manifesting higher New York Heart
ssociation functional class and more digoxin use, as well as
greater prevalence of diabetes; 3) despite these confound-
ng factors, increased QTVI was associated with an inde-
endent risk for VT or VF resulting in defibrillator therapy
ith a hazard ratio of 1.80; 4) normalized QT variability
nadjusted for heart rate variability (QTVN) was associated
ith an even greater risk for combined VT/VF with a
azard ratio of 2.18; and 5) increased QTVN, as opposed to
TVI, was not associated with higher mortality in the
efibrillator arm, suggesting that QTVN is somewhat more
pecific for identifying vulnerability to reentrant ventricular
rrhythmias (which are interrupted by an ICD therapy).
T variability and reentrant arrhythmias. Heterogeneity
f repolarization (and excitability) is necessary for the
nitiation and maintenance of reentrant arrhythmias. Our
nding that increased QT variability is associated with
pontaneous VT/VF supports the interpretation that tem-
oral instability coexists with regional heterogeneity in
epolarization. Further study will be required to determine
hether temporal variability represents a causal factor for
rrhythmia generation or merely an epiphenomenon.
T variability and mortality. The QT variability in the
ighest quartile was not associated with greater mortality
n the conventionally treated arm, although there was a
rend towards an increase in deaths thought to be
rrhythmic in this group. In the defibrillator arm, an
ncrease in mortality was seen in those subjects with
ncreased QTVI but not QTVN. These “defibrillator-
esistant” deaths are presumably due to progressive heart
ailure rather than arrhythmias. In a recent prospective
tudy of outpatients with heart failure, reduced heart rate
ariability was an independent predictor of death due to
rogressive pump dysfunction rather than sudden death
15). Because the QTVI includes a term for heart rate
ariability, an increase in QTVI may predict heart failure
rogression, while the QTVN appears to be more clearly
ssociated with risk for VT/VF.
The MADIT II study has resulted in a significant
roadening of the indications for prophylactic defibrilla-
or implantation, making more than one million Amer-
cans eligible (16). Clinical indexes that could identify
ubjects at highest (or lowest) risk for life-threatening
entricular arrhythmias are lacking, perhaps reflecting our
ncomplete understanding of the mechanisms leading to
T/VF. A recent prospective study of 700 postinfarction
atients found that measures of autonomic tone and
onventional ECG variables did not predict sudden
ardiac death. Ejection fraction, the presence of unsus-
ained VT, and an abnormal signal-average ECG only
eakly predicted sudden death (17). The use of defibril-
ator interrogation in the MADIT II, however, allowed
he accurate identification of arrhythmic events and was
ot reliant on presumptive diagnoses. Markedly increased
T variability (unadjusted for heart rate variability) istrongly associated with a significant increase in risk for
T/VF in the MADIT II population; this finding needs
o be tested further in subjects with less severe myocardial
isease. Unfortunately, the converse does not appear to
e true; presence of low QT variability does not predict
reedom from serious ventricular arrhythmias in a postin-
arction subject with significant left ventricular dysfunc-
ion, at least when measured at rest in a single session. So
hile QT variability appears to identify significant ar-
hythmic vulnerability, it cannot be used to identify the
ndividual who will not benefit from defibrillator implan-
ation. The negative predictive power of the QTVN may
e improved by combining it with a measure of depolar-
zation function, such as QRS duration or signal-
veraged ECG, or perhaps by repeating the assessment at
eriodic intervals or during an exercise challenge.
In conclusion, increased QT variability, a marker of
epolarization lability, is associated with a substantially
ncreased risk for arrhythmic events (documented by inter-
ogating implanted defibrillators) in postinfarction patients
ith severe left ventricular dysfunction.
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